NFE2L2 and neoplasm: Although Nrf2 was initially recognized as a target of chemotherapeutic compounds with the ability to activate this transcription factor [155,156], to date, a large amount of data have been accumulated that show that Nrf2 is the driving force of cancer progression, metastasis, and resistance of tumor cells to the treatment [157,158,159,160].